Search research articles
Contact Us
Filters
Showing results (81-90 of 101) with videos related to
Page
of 11
Sort By:
Advances in Hematology
|
April 12, 2014
Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin's Primary Bone Lymphoma
A Schmidt-Tanguy, R Houot, S Lissandre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1997
Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. The GOELAMS Group, France
C Foussard, B Desablens, L Sensebe, et al.
Bone Marrow Transplantation
|
September 5, 2006
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group
Ph Colombat, A Lemevel, P Bertrand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 8, 2005
Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies
C Foussard, P Colombat, H Maisonneuve, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1996
Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients
P Colonna, J P Jais, B Desablens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 1998
Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stages
J M Andrieu, J P Jais, P Colonna, et al.
Seminars in Oncology
|
April 30, 2003
Transplantation in Waldenstrom's macroglobulinemia--the French experience
O Tournilhac, V Leblond, R Tabrizi, et al.
Blood
|
October 6, 2001
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
M Leporrier, S Chevret, B Cazin, et al.
Blood
|
October 25, 2001
Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease
V Leblond, V Lévy, F Maloisel, et al.
Blood
|
August 15, 1996
Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study
E Solary, B Witz, D Caillot, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 101) with videos related to
Sort By:
Page
of 11
Advances in Hematology
|
April 12, 2014
Results of a Prospective Study of High-Dose or Conventional Anthracycline-Cyclophosphamide Regimen Plus Radiotherapy for Localized Adult Non-Hodgkin's Primary Bone Lymphoma
A Schmidt-Tanguy, R Houot, S Lissandre, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 1, 1997
Is the International Prognostic Index for aggressive lymphomas useful for low-grade lymphoma patients? Applicability to stage III-IV patients. The GOELAMS Group, France
C Foussard, B Desablens, L Sensebe, et al.
Bone Marrow Transplantation
|
September 5, 2006
High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group
Ph Colombat, A Lemevel, P Bertrand, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 8, 2005
Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies
C Foussard, P Colombat, H Maisonneuve, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1996
Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin's disease treated by ABVD plus radiotherapy: ten-year results of the Paris-Ouest-France 81/12 trial, including 262 patients
P Colonna, J P Jais, B Desablens, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 29, 1998
Ten-year results of a strategy combining three cycles of ABVD and high-dose extended irradiation for treating Hodgkin's disease at advanced stages
J M Andrieu, J P Jais, P Colonna, et al.
Seminars in Oncology
|
April 30, 2003
Transplantation in Waldenstrom's macroglobulinemia--the French experience
O Tournilhac, V Leblond, R Tabrizi, et al.
Blood
|
October 6, 2001
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
M Leporrier, S Chevret, B Cazin, et al.
Blood
|
October 25, 2001
Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia in first relapse or with primary refractory disease
V Leblond, V Lévy, F Maloisel, et al.
Blood
|
August 15, 1996
Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study
E Solary, B Witz, D Caillot, et al.
Page
of 11